Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

April 5, 2025

Study Completion Date

April 5, 2025

Conditions

EBV Associated Lymphoma

Interventions

BIOLOGICAL

EBV-specific T cells

Consolidative cellular immunotherapy consisting of one (or up to 4) infusion of ex vivo expanded T cells

Trial Locations (1)

RECRUITING

Ciusss-Emtl, Montreal

All Listed Sponsors

lead

Ciusss de L'Est de l'Île de Montréal

OTHER